CJC 1295 with DAC
Presentation: 2 cc vial, 2 mg/vial, protected with hologram. Comes without solvent.
CJC 1295 with dac (synonym CJC1295/DAC, modified form (GRF 1-29) with drug affinity complex) belongs to class of tetrasubtituted peptide hormones and contains 30 amino acids; also it can be described as analog of GH releasing hormone. Its molecular formula is C165H269N47O46 and its molecular mass is 3647.28.
CJC 1295 with DAC-complex was the first time developed and produced by Canadian scientists with initial purpose to find way to increase effective half-life period of growth hormone release hormone. The very first clinical studies regarding this research compound took place in the year of 2000. In 2006 a study concerning efficacy and effectiveness as well as safety profile of CJC 1295/DAC was done, it includes two double-blind, randomized, placebo-controlled trials.
Due to having DAC-complex this research compound possesses greater binding affinity towards GHRH receptors, which in turn protects that hormone from degradation. CJC1295 w/t dac-complex also stimulates production of hormone of growth and IGF-1 without increasing of prolactin, and that leads to effective fat loss. The same time it has ability to promote synthesis of proteins and therefore increasing growth of muscle tissues.
These representatives of synthetic peptides must not be used in human treatment but are produced for use in special laboratories only.
This synthetic compound is not for common human consumption.